La radio-chimiothérapie exclusive des cancers bronchiques non à petites cellules

In locally advanced inoperable non-small cell lung cancer (NSCLC) patients, combined radiotherapy and platinum-based chemotherapy, administered concomitantly in good performance status patients, is the standard treatment. Based on a meta-analysis of randomized studies comparing sequential chemoradiotherapy (CTRT) to concomitant CTRT, there was a benefit in favour of concurrent CTRT with a 5-year survival of 15%. In recent phase II, III studies where more conformal RT was used, reported median survival was over 24 months. The implementation of new techniques of optimized conformal radiotherapy and the integration of new systemic therapies, as well as targeted agents according to the molecular profile of patients constitute some of the areas of research for the future. Inclusion of patients in prospective studies is warranted to improve the outcome of locally advanced NSCLC.